Live Analyst Rating Changes 1777 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jonathan Miller
EVR
Jonathan Miller
Evercore ISI
Wall Street Analyst
★★☆☆☆
#1895
on 13Foresight · ranked by our own returns
43%
Success Rate
-1.6%
Average Return
9 of 21 calls profitable · -10.1% vs benchmark
📈 Across the calls we could measure, roughly 43% of Jonathan Miller's ratings turned a profit when each position was held for 1 year — averaging -1.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

36 Buy 4 Hold 0 Sell
Jonathan's Stock Coverage 23 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
EDIT
Editas Medicine
 May 27, 2026 BUY Buy
+408.0% avg upside
33 analysts
$15.00
457.65% Upside
 -25.9%
NKTX
Nkarta
 May 18, 2026 BUY Strong Buy
+552.7% avg upside
15 analysts
$9.00
214.65% Upside
 ·
JANX
Janux Therapeutics Inc
 May 11, 2026 BUY Strong Buy
+217.2% avg upside
21 analysts
$22.00
54.77% Upside
 -0.6%
CRSP
Crispr Therapeutics AG
 May 11, 2026 BUY Buy
+39.1% avg upside
41 analysts
$76.00
40.42% Upside
 +0.1%
TRDA
Entrada Therapeutics Inc
 May 05, 2026 BUY Strong Buy
+198.5% avg upside
10 analysts
$25.00
252.56% Upside
 -56.8%
ERAS
Erasca
 Apr 28, 2026 BUY Strong Buy
+39.0% avg upside
14 analysts
$24.00
75.56% Upside
 +41.2%
NTLA
Intellia Therapeutics
 Apr 28, 2026 HOLD Buy
+151.9% avg upside
37 analysts
$16.00
2.04% Upside
 -8.3%
FDMT
4D Molecular Therapeutics
 Apr 13, 2026 BUY Strong Buy
+265.2% avg upside
15 analysts
$23.00
138.09% Upside
 -8.9%
AURA
Aura Biosciences Inc
 Apr 13, 2026 BUY Strong Buy
+233.5% avg upside
9 analysts
$15.00
136.69% Upside
 -7.2%
PMVP
PMV Pharmaceuticals
 Apr 13, 2026 BUY Strong Buy
+1200.9% avg upside
12 analysts
$4.00
253.94% Upside
 -4.4%
ZYME
Zymeworks
 Mar 09, 2026 BUY Strong Buy
+40.3% avg upside
25 analysts
$48.00
107.49% Upside
 -4.6%
CRBU
Caribou Biosciences
 Mar 09, 2026 BUY Strong Buy
+581.8% avg upside
12 analysts
$13.00
692.77% Upside
 +8.6%
RCUS
Arcus Biosciences
 Mar 02, 2026 BUY Strong Buy
+38.1% avg upside
20 analysts
 — +0.8%
ARVN
Arvinas Holding Company
 Feb 25, 2026 BUY Strong Buy
+264.5% avg upside
27 analysts
$19.00
147.72% Upside
 -42.3%
OKUR
OnKure Therapeutics
 Jan 26, 2026 BUY Buy
+428.2% avg upside
12 analysts
 — +11.6%
AVIR
Atea Pharmaceuticals
 Nov 28, 2025 BUY Buy
+49.1% avg upside
6 analysts
$6.00
37.64% Upside
 +44.8%
ENTA
Enanta Pharmaceuticals
 Sep 30, 2025 BUY Buy
+159.2% avg upside
17 analysts
$12.00
5.23% Downside
 +10.4%
STTK
Shattuck Labs
 Oct 02, 2024 BUY Strong Buy
+369.1% avg upside
14 analysts
 — +89.6%
MGNX
MacroGenics
 Sep 16, 2024 BUY Buy
+326.1% avg upside
25 analysts
 — -57.1%
PROK
ProKidney
 Sep 02, 2022 BUY Buy
+260.7% avg upside
12 analysts
 — -15.3%
VAXX
Vaxxinity Inc
 Apr 27, 2022 HOLD Buy
+73233.4% avg upside
4 analysts
 — ·
ATRA
Atara Biotherapeutics
 May 05, 2021 BUY Buy
+79.6% avg upside
18 analysts
 — -49.5%
SQZB
SQZ Biotechnologies
 Jan 07, 2021 BUY Buy
+102677.7% avg upside
7 analysts
 — ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jonathan Miller — Frequently Asked Questions
How accurate are Jonathan Miller's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Jonathan's ratings were profitable over a one-year hold, with an average return of -1.6% per rating, or -10.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jonathan ranked on 13Foresight?
Jonathan Miller is currently ranked #1895 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jonathan cover?
Jonathan most recently has ratings on EDIT, NKTX, JANX, CRSP, TRDA, ERAS, NTLA, FDMT, AURA, PMVP, ZYME, CRBU and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.